Azacitidine

Marginal Zone Lymphoma

Prelude TherapeuticsSmall moleculePhase 2Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 73/ 100

Competitive context

105 Active assets in the Marginal Zone Lymphoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE University of Miami	Phase 2	BBB
Fludarabine Paolo Caimi, MD	Phase 2	BBB
Orelabrutinib Henan Cancer Hospital	Phase 4	BBB
CYCLOSPORIN A Fred Hutchinson Cancer Center	Phase 2	BBB
FILGRASTIM Fred Hutchinson Cancer Center	Phase 2	BBB

View all 50 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

73 / 100

acute erythroid leukemiaDormant

BB

Indicative ·

71 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.